stonks4u
Sign up free
SMMT logo

SMMT Summit Therapeutics Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$13.35
-0.65 (-4.64%)

Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an ora…

Market Cap: $10.65Bwww.smmttx.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

100
808793100
Aug 9Aug 12

Quote

Day Range
$12.99 – $13.70
52-Week Range
$12.25 – $30.05
Volume
$9.74M
Market Cap
$10.65B
50-Day Avg
$14.24
200-Day Avg
$16.74
Prev Close
$14.00
Open
$13.60

Valuation & Ratios

P/E Ratio
-12.15
EPS
$-1.44
P/B Ratio
26.74
P/S Ratio
0.00
Debt/Equity
0.03
Current Ratio
9.87
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
-220.8%
Return on Assets
-193.6%
FCF Yield
-1.8%
EV/EBITDA
-11.97

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$0.00$-1.08B$-1.44
2024$0.00$-176.77M$-0.25
2023$0.00$-482.37M$-0.78
2022$583.2K$-65.17M$-0.34
2021$1.34M$-65.52M$-0.71

Social Signal Score

43
5d
50
1 mentions
—
30d
41
2 mentions
—
60d
41
2 mentions
—
90d
41
2 mentions
—
rss: 1 · news: 1

Earnings

Mon, Oct 19(in 2 months)

Consensus estimate $-0.28 per share

3of 7 quarters beat consensus

Typical surprise -2.0% (median, so one quarter with a near-zero estimate can't distort it)

  • Thu, Jul 23$-0.28 vs $-0.27miss
  • Thu, Apr 30$-0.24 vs $-0.33beat
  • Mon, Feb 23$-0.29 vs $-0.10miss
  • Mon, Oct 20$-0.31 vs $-0.18miss
  • Mon, Aug 11$-0.76 vs $-0.09miss
  • Thu, May 1$-0.09 vs $-0.09beat

Estimates and results for SMMT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

SMMThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (2)

  • Newsbusinesswire.com·3d ago·Neutral

    Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that, on August 12, 2026, its partner Akeso Inc. (Akeso, HKEX Code: 9926.HK) announced receipt of marketing authorization in China from the National Medical Products Administration (NMPA) for the use of ivonescimab, a novel, potential first-in-class investigational bispecifi

    View source ↗
  • News (RSS)thisismoney·6d ago·Negative

    The most popular Chinese car brands in Britain: From small fry to the maker selling 1 in 25 of all new cars Based on the latest year-to-date figures SMMT, we've ranked Chinese carmakers by market share to see which has secured the largest slice of the UK automotive pie.

    View source ↗